The management of the type 2 diabetic patient with hypertension - Too late and too little: Suggested improvements

Blood Pressure

Volumn 17, Issue 5-6, 2008, Pages 250-259

  Rydén, Lars ^a   Waeber, Bernard ^b   Ruilope, Luis M ^c   Mancia, Giuseppe ^d   Volpe, Massimo ^e   Holzgreve, Heinrich ^f   Mogensen, Carl Erik ^g   Laurent, Stephane ^h  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d SAN GERARDO HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Kardiologische Praxis   (Germany)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Combination therapy; Hypertension; Management; Renin angiotensin system; Type 2 diabetes

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 58049097519     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050802513387     Document Type: Review

References (80)

1. Murray, C. J. and Lopez, A. D. (1996) Evidence-based health policy - Lessons from the Global Burden of Disease Study. Science, 274, pp. 740-743.
2. Amos, A. F., McCarty, D. J. and Zimmet, P. (1997) The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabetic Med, 14, pp. S1-S85.
3. Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S. and Murray, C. J. (2002) Selected major risk factors and global and regional burden of disease. Lancet, 360, pp. 1347-1360.
4. Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K. and He, J. (2005) Global burden of hypertension: Analysis of worldwide data. Lancet, 365, pp. 217-223.
5. Tarnow, L., Rossing, P., Gall, M. A., Nielsen, F. S. and Parving, H. H. (1994) Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care, 17, pp. 1247-1251.
6. Hypertension in Diabetes Study (HDS): I (1993) Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens, 11, pp. 309-317.
7. Kannel, W. B., Wilson, P. W. and Zhang, T. J. (1991) The epidemiology of impaired glucose tolerance and hypertension. Am Heart J, 121, pp. 1268-1273.
8. Leiter, L. A., Barr, A., Belanger, A., Lubin, S., Ross, S. A. Tildesley, H. D. et al. (2001) Diabetes screening in Canada (DIASCAN) study. Diabetes Care, 24, pp. 1038-1043.
9. Savage, G., Ewing, P., Kirkwood, H. and Carter, S. (2003) Are undiagnosed IGT/IFG and type 2 diabetes common in heart disease and hypertension?. Br J Diabetes Vasc Dis, 3, pp. 414-416.
10. Hypertension in Diabetes Study (HDS): II (1993) Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens, 11, pp. 319-325.
11. Stamler, J. (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16, pp. 434-444.
12. Kannel, W. B., Neaton, J. D., Wentworth, D., Thomas, H. E., Stamler, J. Hulley, S. B. et al. (1986) Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J, 112, pp. 825-836.
13. Stokes, J., Kannel, W. B. and Wolf, P. A. (1987) The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation, 75, p. 65.
14. Haffner, S. M., Stern, M. P., Hazuda, H. P., Mitchell, B. D. and Patterson, J. K. (1990) Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA, 263, pp. 2893-2898.
15. Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O'Donnell, C. J. Kannel, W. B. et al. (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med, 345, pp. 1291-1297.
16. Kearney, P. M., Whelton, M., Reynolds, K., Whelton, P. K. and He, J. (2004) Worldwide prevalence of hypertension: A systematic review. J Hypertens, 22, pp. 11-19.
17. Erdine, S. and Aran, S. N. (2004) Current status of hypertension control around the world. Clin Exper Hypertens, 26, pp. 731-738.
18. Wang, Y. R., Alexander, G. C. and Stafford, R. S. (2007) Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med, 167, pp. 141-147.
19. Parnes, B. L., Main, D. S., Dickinson, L. M., Niebauer, L., Holcomb, S. Westfall, J. M. et al. (2004) Clinical decisions regarding HbA1c results in primary care: A report from CaReNet and HPRN. Diabetes Care, 27, pp. 13-16.
20. Beckles, G. L., Engelgau, M. M., Narayan, K. M., Herman, W. H., Aubert, R. E. and Williamson, D. F. (1998) Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care, 21, pp. 1432-1438.
21. Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J. de Boer, M. J. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 28, pp. 88-136.
22. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R. Germano, G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 28, pp. 1462-1536.
23. Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G. Cifkova, R. et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil, 14, pp. 1-113.
24. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. Izzo Jr, J. L. et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA, 289, pp. 2560-2572.
25. American Diabetes Association (2007) Standards of medical care in diabetes - 2007. Diabetes Care, 30, pp. 4-41.
26. Wang, Y. and Wang, Q. J. (2004) The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: New challenges of the old problem. Arch Intern Med, 164, pp. 2126-2134.
27. Cordero, A., Laclaustra, M., Leon, M., Grima, A., Casasnovas, J. A. Luengo, E. et al. (2006) Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens, 19, pp. 189-196.
28. Balkau, B., Shipley, M., Jarrett, R. J., Pyorala, K., Pyorala, M. Forhan, A. et al. (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care, 21, pp. 360-367.
29. Alderman, M. H., Cohen, H. and Madhavan, S. (1999) Diabetes and cardiovascular events in hypertensive patients. Hypertension, 33, pp. 1130-1134.
30. Vasan, R. S., Beiser, A., Seshadri, S., Larson, M. G., Kannel, W. B. D'Agostino, R. B. et al. (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA, 287, pp. 1003-1010.
31. Julius, S., Nesbitt, S. D., Egan, B. M., Weber, M. A., Michelson, E. L., Kaciroti, N. Trial of Preventing Hypertension (TROPHY) Study Investigators et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. New Engl J Med, 354, pp. 1685-1697.
32. Turnbull, F., Neal, B., Algert, C., Chalmers, J., Chapman, N. Cutler, J. et al. (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med, 165, pp. 1410-1419.
33. Mancia, G. (2005) The association of hypertension and diabetes: Prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetologica, 42, pp. S17-S25.
34. Burnier, M. and Zanchi, A. (2006) Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens, 24, pp. 11-25.
35. Schrier, R. W., Estacio, R. O., Esler, A. and Mehler, P. (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int, 61, pp. 1086-1097.
36. Schrier, R. W., Estacio, R. O., Mehler, P. S. and Hiatt, W. R. (2007) Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial. Nat Clin Pract Nephrol, 3, pp. 428-438.
37. Patel, A., ADVANCE Collaborative Group, MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L. Harrap, S. et al. (2007) Effects of fixed combination of perindopril and indapamide on microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet, 370, pp. 829-840.
38. Gaede, P., Lund-Andersen, H., Parving, H. H. and Pedersen, O. (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 358, pp. 580-591.
39. Colhoun, H. M., Betteridge, D. J. Durrington, P. N. et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet, 364, pp. 685-696.
40. Pyorala, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G. and Thorgeirsson, G. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 20, pp. 614-620.
41. Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moye, L. A., Howard, B. V. Howard, W. J. et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation, 98, pp. 2513-2519.
42. Adler, A. I., Stratton, I. M. Neil, H. A. et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. Br Med J, 321, pp. 412-419.
43. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317, pp. 703-713.
44. Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N. and Schrier, R. W. (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med, 338, pp. 645-652.
45. Estacio, R. O., Jeffers, B. W., Gifford, N. and Schrier, R. W. (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care, 23, pp. 54-64.
46. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D. Julius, S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351, pp. 1755-1762.
47. Zanchetti, A., Hansson, L., Clement, D., Elmfeldt, D., Julius, S. Rosenthal, T. et al. (2003) HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: Does a J-shaped curve exist in smokers?. J Hypertens, 21, pp. 797-804.
48. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet, 355, pp. 253-259.
49. Weidmann, P. (2001) Metabolic profile of indapamide sustained-release in patients with hypertension: Data from three randomised double-blind studies. Drug Safety, 24, pp. 1155-1165.
50. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 358, pp. 2545-2559.
51. Perneger, T. V., Brancati, F. L., Whelton, P. K. and Klag, M. J. (1994) End-stage renal disease attributable to diabetes mellitus. Ann Intern Med, 121, pp. 912-998.
52. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E. Parving, H. H. et al. (2001) RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345, pp. 861-869.
53. Parving, H. H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S. and Arner, P. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 345, pp. 870-878.
54. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A. Lewis, J. B. et al. (2001) Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345, pp. 851-860.
55. Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P. Brusegan, V. et al. (2004) Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 351, pp. 1941-1951.
56. Mancia, G., Ambrosioni, E., Rosei, E. A., Leonetti, G., Trimarco, B. and Volpe, M. (2005) Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: Results of the ForLife study. J Hypertens, 23, pp. 1575-1581.
57. Volpe, M., Rosei, E. A., Ambrosioni, E., Leonetti, G., Trimarco, B. and Mancia, G. (2007) Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: Results from the ForLife study in Italy. J Hypertens, 25, pp. 2390-2397.
58. Dahlof, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G. Caulfield, M. et al. (2005) ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet, 366, pp. 895-906.
59. Law, M. R., Wald, N. J., Morris, J. K. and Jordan, R. E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ, 326, pp. 1427-1431.
60. Brunner, H. R., Menard, J., Waeber, B., Burnier, M., Biollaz, J. Nussberger, J. et al. (1990) Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations. J Hypertens, 8, pp. 3-11.
61. Ruzicka, M. and Leenen, F. H. (2001) Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs, 61, pp. 943-954.
62. Brown, M. J., Castaigne, A., de Leeuw, P. W., Mancia, G., Palmer, C. R. Rosenthal, T. et al. (2000) Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension, 35, pp. 1038-1042.
63. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288, pp. 2981-2997
64. Dahlof, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U. LIFE Study Group et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359, pp. 995-1003.
65. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H. and Pedersen, O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 348, pp. 383-393.
66. Jones, P. H. (2007) Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol, 99, pp. 133B-140B.
67. Solano, M. P. and Goldberg, R. B. (2006) Management of dyslipidemia in diabetes. Cardiol Rev, 14, pp. 125-135.
68. Nicolucci, A., De Berardis, G., Sacco, M. and Tognoni, G. (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: How the same data generate divergent conclusions. Eur Heart J, 28, pp. 1925-1927.
69. Schmieder, R. E., Hilgers, K. F., Schlaich, M. P. and Schmidt, B. M. (2007) Renin-angiotensin sy stem and cardiovascular risk. Lancet, 369, pp. 1208-1219.
70. Duprez, D. A. (2006) Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. J Hypertens, 24, pp. 983-991.
71. Lipinski, B. (2001) Pathophysiology of oxidative stress in diabetes mellitus. J Diab Complic, 15, pp. 203-210.
72. Lassegue, B. and Griendling, K. K. (2004) Reactive oxygen species in hypertension; An update. Am J Hypertens, 17, pp. 852-860.
73. Mehta, J. L., Rasouli, N., Sinha, A. K. and Molavi, B. (2006) Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int J Biochem Cell Biol, 38, pp. 794-803.
74. Dandona, P., Dhindsa, S., Ghanim, H. and Chaudhuri, A. (2007) Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens, 21, pp. 20-27.
75. Leung, P. S. (2007) Mechanisms of protective effects induced by blockade of the renin-angiotensin system: Novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diab Med, 24, pp. 110-116.
76. Ruilope, L. M. (2005) Renin-angiotensin-aldosterona system blockade and renal protection: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?. Acta Diabetol, 42, pp. S33-S41.
77. Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K. and for the AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med, 358, pp. 2433-2446.
78. Prasad, A. (2004) Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 110, pp. 1507-1512.
79. Mancia, G., Grassi, G. and Zanchetti, A. (2006) New-onset diabetes and antihypertensive drugs. J Hypertens, 24, pp. 3-10.
80. Elliott, W. J. and Meyer, P. M. (2007) Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet, 369, pp. 201-207.